<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005987</url>
  </required_header>
  <id_info>
    <org_study_id>1996LS137</org_study_id>
    <secondary_id>UMN-MT-9216</secondary_id>
    <secondary_id>UMN-MT-1992-16</secondary_id>
    <nct_id>NCT00005987</nct_id>
  </id_info>
  <brief_title>Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to&#xD;
      give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating&#xD;
      factors such as filgrastim and sargramostim may increase the number of immune cells found in&#xD;
      bone marrow or peripheral blood and may help a person's immune system recover from the side&#xD;
      effects of chemotherapy. Interferon alfa may interfere with the growth of cancer cells. It is&#xD;
      not yet known which treatment regimen is more effective for multiple myeloma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of filgrastim with that of&#xD;
      sargramostim plus chemotherapy, peripheral stem cell transplantation, and interferon alfa in&#xD;
      treating patients who have multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare disease control and extended survival in patients with multiple myeloma when&#xD;
           treated with either filgrastim (G-CSF) or sargramostim (GM-CSF) plus high-dose&#xD;
           chemotherapy followed by autologous peripheral blood stem cell (PBSC) transplantation&#xD;
           followed by interferon alfa.&#xD;
&#xD;
        -  Determine whether these priming treatments induce sufficient mobilization of circulating&#xD;
           PBSC to allow their collection by leukapheresis for subsequent use in autologous&#xD;
           transplantation in these patients.&#xD;
&#xD;
        -  Determine whether these treatments induce complete response in conjunction with rapid&#xD;
           hematopoietic recovery and modest transplant-associated morbidity and mortality in this&#xD;
           patient population.&#xD;
&#xD;
        -  Determine whether interferon alfa, given as maintenance immunostimulatory therapy for&#xD;
           patients achieving significant cytoreduction post transplantation, can prevent or delay&#xD;
           malignant relapse in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: In the priming phase, patients receive cyclophosphamide IV over 2 hours on day 1,&#xD;
           mitoxantrone IV over 1 hour daily on days 1-2, and dexamethasone IV every 12 hours&#xD;
           beginning on day 1 for a total of 4 doses. Patients also receive sargramostim (GM-CSF)&#xD;
           IV over 2 hours or subcutaneously (SC) daily beginning 48 hours after the last dose of&#xD;
           mitoxantrone and continuing until completion of leukapheresis. Peripheral blood stem&#xD;
           cells (PBSC) are collected daily on days 11-13 after neutrophil recovery.&#xD;
&#xD;
        -  Arm II: In the priming phase, patients receive the same treatment as in arm I except&#xD;
           these patients receive filgrastim (G-CSF) IV over 15 minutes or SC in place of GM-CSF.&#xD;
&#xD;
      In the transplant phase, patients who have not received prior radiotherapy receive&#xD;
      cyclophosphamide IV over 2 hours daily on days -6 and -5 and total body irradiation twice&#xD;
      daily on days -3 through -1. Autologous PBSC are reinfused on day 0. Patients also receive&#xD;
      GM-CSF IV over 2 hours daily and G-CSF IV over 15 minutes daily beginning on day 0 and&#xD;
      continuing until day 28 or until blood counts recover.&#xD;
&#xD;
      Patients who have received prior radiotherapy receive cyclophosphamide IV over 2 hours daily&#xD;
      on days -6 through -3, carmustine IV over 1 hour on day -6, and etoposide IV over 4 hours&#xD;
      every 12 hours for a total of 6 doses on days -6 through -4. Autologous PBSC are reinfused on&#xD;
      day 0. Patients also receive GM-CSF IV over 2 hours daily and G-CSF IV over 15 minutes daily&#xD;
      beginning on day 0 and continuing until day 28 or until blood counts recover.&#xD;
&#xD;
      All patients then receive interferon alfa SC 3 times weekly starting on day 28 and continuing&#xD;
      until relapse or disease progression.&#xD;
&#xD;
      Patients may also undergo radiotherapy 5 days a week for 2 weeks for residual bony lesions&#xD;
      measuring greater than 2 cm.&#xD;
&#xD;
      Patients are followed at days 28 and 100, and at 6, 9, 12, 18, 24, 30, and 36 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-35 patients will be accrued for this study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn because treatment guidelines changed&#xD;
  </why_stopped>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">87</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma&#xD;
&#xD;
               -  Complete or partial remission after initial therapy OR&#xD;
&#xD;
               -  Complete or partial response to therapy after disease progression following&#xD;
                  initial therapy&#xD;
&#xD;
               -  No plasma cell leukemia (greater than 10% circulating plasma cells)&#xD;
&#xD;
               -  No advanced myeloma refractory and unresponsive to at least 2 salvage&#xD;
                  chemotherapy regimens&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  70 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  Karnofsky 80-100%&#xD;
&#xD;
          -  Under 65 years:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL (untransfused)&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (untransfused)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  ALT less than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  Creatinine clearance greater than 60 mL/min (if creatinine at least 1.5 mg/dL)&#xD;
&#xD;
          -  Under 65 years:&#xD;
&#xD;
               -  Creatinine less than 2 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  LVEF at least 45%&#xD;
&#xD;
          -  Under 65 years:&#xD;
&#xD;
               -  No active ischemia&#xD;
&#xD;
               -  LVEF greater than 45% by MUGA&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  If history of smoking or respiratory symptoms, spirometry and DLCO must be&#xD;
                  greater than 50% of predicted&#xD;
&#xD;
          -  Under 65 years:&#xD;
&#xD;
               -  FEV_1 and FVC greater than 60% predicted&#xD;
&#xD;
               -  DLCO greater than 50% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. Weisdorf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

